Please ensure Javascript is enabled for purposes of website accessibility
Home / Products / Super-Affinity Antibody

Anti-Human CD19 Antibody (FMC63), PE

Catalog #:   FHD10842 Specific References (50) DATASHEET
Host species: Mouse
Isotype: IgG2a, kappa
Applications: ELISA, FCM, IF
Accession: P15391
Overview

Catalog No.

FHD10842

Species reactivity

Human

Host species

Mouse

Isotype

IgG2a, kappa

Clonality

Monoclonal

Conjugation

PE

Target

CD19, Differentiation antigen CD19, T-cell surface antigen Leu-12, B-lymphocyte antigen CD19, B-lymphocyte surface antigen B4

Concentration

0.5 mg/ml

Endotoxin level

Please contact with the lab for this information.

Accession

P15391

Applications

ELISA, FCM, IF

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4, 0.2% BSA, 0.05% Proclin 300.

Stability and Storage

Store at 4°C for 12 months. Protect from light. Do not freeze.

Clone ID

FMC63

Data Image
References

Immune cell aberrations in Systemic Lupus Erythematosus: navigating the targeted therapies toward precision management., PMID:40524185

Correlation with CD79B expression and clinicopathological parameters including cell of origin, CD79A and CD19 expression, and CD79B mutation in diffuse large B-cell lymphoma., PMID:40523447

Beyond BCL2 (B cell lymphoma) and BTK (Bruton tyrosine kinase) inhibitors: novel agents and resistance mechanisms for chronic lymphocytic leukemia., PMID:40515863

[Modern systemic treatment-bispecific antibodies and CAR-T cell therapy : Clinical management, mechanisms of action, outcomes]., PMID:40514410

Pharmacokinetics, Receptor Occupancy, and Pharmacodynamics of Obexelimab Following Intravenous Administration in Adult Healthy Volunteers and in Patients With Rheumatoid Arthritis., PMID:40512061

Perspectives on T-cell engaging therapies in relapsed/refractory indolent non-Hodgkin lymphoma., PMID:40511598

Influence of Ovophospholipids on Lymphocyte Subsets and Humoral Immune Response in Mice., PMID:40509141

Increased Effector Memory CD4+ T Cells Are Associated with Chronic Childhood Immune Thrombocytopenia., PMID:40505868

QSP modeling of loncastuximab tesirine with T-cell-dependent bispecific antibodies guides dose-regimen strategy., PMID:40500294

Treatment of Older Adults with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia., PMID:40494331

Blinatumomab Use in Pediatric B-ALL: Where are we now?, PMID:40489801

Monitoring anti-Rituximab antibodies in myasthenia gravis affects the time to event during Rituximab treatment., PMID:40488894

Advances in the treatment of ANCA-associated vasculitis., PMID:40473820

Peripheral memory B cell population maintenance and long-term survival after perioperative chemoimmunotherapy in NSCLC (NADIM trial)., PMID:40468805

Autoantibodies Targeting Vinculin Reveal Novel Insight into the Mechanisms of Autoimmune Podocytopathies., PMID:40463498

Recent advances in monoclonal antibody development for treatment of B-cell acute lymphoblastic leukemia., PMID:40455243

Multi-courses of blinatumomab combined with reduced dose chemotherapy has been successfully used in chemo-intolerant middle to high-risk pediatric B-ALL patients with invasive fungal disease., PMID:40445300

Long-Term Effectiveness and Safety of Rituximab in Neuromyelitis Optica Spectrum Disorder: A 5-Year Observational Study., PMID:40442445

Nanobody-Directed CEA-targeting CAR T Cells Eliminate Gastrointestinal Cancer Xenografts., PMID:40439687

Siglec6 CAR T cells suppressed progression of AML via inhibiting Siglec6 and SHP2 induced Src and ERK signaling activation., PMID:40436895

CD19+IL-10+ regulatory B cells induced by IL-12p35 regulates functional T-cell subsets in patients with immune thrombocytopenia., PMID:40415408

Extracellular Inosine Induces Anergy in B Cells to Alleviate Autoimmune Hepatitis., PMID:40409684

Revolutionizing Autoimmune Kidney Disease Treatment with Chimeric Antigen Receptor-T Cell Therapy., PMID:40405911

IGM-7354, an immunocytokine with IL-15 fused to an anti-PD-L1 IgM, induces NK and CD8+ T cell-mediated cytotoxicity of PD-L1 positive tumor cells., PMID:40402523

Optimal Structural Designs of Trispecific Antibodies to Enhance Therapeutic Efficacy in Solid Tumors and Hematological Malignancies., PMID:40402462

Lymphocyte Subsets in Covid-19 Saudi Patients: Infection Caused Significant Reduction in Peripheral Blood Lymphocyte Subset., PMID:40387754

Relapses during treatment with monoclonal antibodies targeting B-cells in NMOSD., PMID:40383834

Short-term treatment of CIDP with efgartigimod: a case series in China., PMID:40375986

Modular cell line for scalable and rapid in vitro evaluation of chimeric antigen receptors., PMID:40374131

Immune responses after one versus two Influenza A/B vaccinations in patients with multiple myeloma., PMID:40372494

Immune rejection of human mesenchymal stem cells compared to extracellular vesicles in mice with renal artery stenosis., PMID:40371959

Molecular characterization and predictors of relapse in patients with Ph + ALL after frontline ponatinib and blinatumomab., PMID:40369607

The role of blinatumomab in adult acute B lymphoblastic leukaemia., PMID:40368871

Targeted delivery of doxorubicin to B-cell lymphoma using monoclonal antibody-functionalized Chaetoceros biosilica., PMID:40360717

Obinutuzumab is effective for the treatment of rituximab-refractory PLA2R-associated membranous nephropathy., PMID:40336511

New Frontiers in Multiple Sclerosis Treatment: From Targeting Costimulatory Molecules to Bispecific Antibodies., PMID:40332536

Quantification of Urine and Plasma Levels of Extracellular Vesicles in a Cohort of Kidney Transplant Recipients and Chronic Kidney Disease Patients., PMID:40332150

The case for targeting latent and lytic Epstein-Barr virus infection in multiple sclerosis., PMID:40327539

Beyond Cellular Therapies: The Expanding Role of Antibody-Driven Immunotherapy in Pediatric Acute Lymphoblastic Leukemia., PMID:40324358

Clinical Features and Factors Associated With Outcome in Late Adult-Onset Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease., PMID:40324120

Expansions of circulating plasmablasts producing commensal-reactive IgA antibodies are predictors for chronic GVHD., PMID:40324063

The evolving therapeutic revolution in adult acute lymphoblastic leukemia., PMID:40323723

Effect of controlled human Plasmodium falciparum infection on B cell subsets in individuals with different levels of malaria immunity., PMID:40321757

Jieduquyuziyin prescription suppresses the activation of the extrafollicular effector B cell by regulating integrin αV signaling in systemic lupus erythematosus., PMID:40318773

Multiplex immunophenotyping of human acute myeloid leukemia patients revealed single -cell heterogeneity with special attention on therapy sensitive and therapy resistant subpopulations., PMID:40313947

CD19+ B cell depletion: a novel strategy to alleviate ischemic stroke damage., PMID:40313936

The bispecific antibody AZD0486: an overview of the clinical journey to date with a focus on follicular lymphoma., PMID:40312112

Management of Adult Acute Lymphoblastic Leukemia: A Review., PMID:40310617

CD22 CAR-T cells secreting CD19 T-cell engagers for improved control of B-cell acute lymphoblastic leukemia progression., PMID:40306957

Generation of a Severe Hemophilia A Humanized Mouse Model Capable of Inducing an Anti-FVIII Immune Response., PMID:40300593

Datasheet
$ 258
Product specifications
50 T 258 100 T 426

Contact Information

Order: order@antibodysystem.com

Mail: support@antibodysystem.com

Distributor list

For research use only. Not for human or drug use.

Need help with your order?

Find out more about placing an order here

Anti-Human CD19 Antibody (FMC63), PE [FHD10842]
Terms of sale Website terms of use Cookie policy Privacy
Copyright © 2025 AntibodySystem SAS. All Rights Reserved.            All Products are for Research Use Only